# Adjuvant Intensification for LAR

> **NCT07407517** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Fudan University** · enrollment: 904 (estimated)

## Conditions studied

- Breast Cancer Females
- Triple Negative Breast Cancer (TNBC)

## Interventions

- **DRUG:** Everolimus 10 mg daily

## Key facts

- **NCT ID:** NCT07407517
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02-01
- **Primary completion:** 2033-02-01
- **Final completion:** 2033-02-01
- **Target enrollment:** 904 (ESTIMATED)
- **Last updated:** 2026-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07407517

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07407517, "Adjuvant Intensification for LAR". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07407517. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*